EU encourages marketing of orphan products:
This article was originally published in Clinica
The European Parliament has approved the EC regulation on orphan medicinal products, giving exclusive marketing rights for 10 years to products that would be unlikely to generate sufficient returns without such incentives. The regulation will cover products that diagnose, prevent or treat, life-threatening, seriously debilitating or serious chronic conditions and will include some products on the drug/device borderline, such as contrast media. Orphan status will be decided by a new committee set up at the European Medicines Evaluation Agency and companies will benefit from a range of incentives, including a reduction in, or a waiver of, registration fees.
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.